{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T12:14:02Z","timestamp":1651580042203},"reference-count":20,"publisher":"PAGEPress Publications","issue":"1","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatismo"],"abstract":"<jats:p>Not available<\/jats:p>","DOI":"10.4081\/reumatismo.2022.1482","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T11:45:06Z","timestamp":1651578306000},"source":"Crossref","is-referenced-by-count":0,"title":["Reply to: \u201cHerpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab\u201d by Josef Finsterer"],"prefix":"10.4081","volume":"74","author":[{"given":"B.","family":"Maranini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ciancio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Cultrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Govoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"1604","doi-asserted-by":"crossref","unstructured":"Maranini B, Ciancio G, Cultrera R, Govoni M. Herpes zoster infection following mRNA COVID-19 vaccine in a patient with ankylosing spondylitis. Reumatismo. 2021; 73: 1445.","DOI":"10.4081\/reumatismo.2021.1445"},{"key":"1605","doi-asserted-by":"crossref","unstructured":"Gershon AA, Breuer J, Cohen JI, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015; 1: 15016.","DOI":"10.1038\/nrdp.2015.16"},{"key":"1606","doi-asserted-by":"crossref","unstructured":"Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020; 7: ofaa005.","DOI":"10.1093\/ofid\/ofaa005"},{"key":"1607","doi-asserted-by":"crossref","unstructured":"Che H, Lukas C, Morel J, Combe B. Risk of herpes\/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014; 81: 215-21.","DOI":"10.1016\/j.jbspin.2013.07.009"},{"key":"1608","doi-asserted-by":"crossref","unstructured":"Ting SW, Ting SY, Lin YS, et al. Risk of herpes zoster in psoriasis patients receiving systemic therapies: a nationwide population-based cohort study. Sci Rep. 2021; 11: 11824.","DOI":"10.1038\/s41598-021-91356-3"},{"key":"1609","doi-asserted-by":"crossref","unstructured":"Chiu YM, Tang CH, Hung ST, et al. A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study. Scand J Rheumatol. 2017; 46: 236-40.","DOI":"10.1080\/03009742.2016.1202318"},{"key":"1610","doi-asserted-by":"crossref","unstructured":"Khazan M, Nasiri S, Riahi SM, et al. Measurement of melatonin, indole-dioxygenase, IL-6, IL-18, ferritin, CRP, and total homocysteine levels during herpes zoster. J Med Virol. 2020; 92: 1253-9.","DOI":"10.1002\/jmv.25484"},{"key":"1611","doi-asserted-by":"crossref","unstructured":"Bauer ME, Fuente Mde L. The role of oxidative and inflammatory stress and persistent viral infections in immunosenescence. Mech Ageing Dev. 2016; 158: 27-37.","DOI":"10.1016\/j.mad.2016.01.001"},{"key":"1612","doi-asserted-by":"crossref","unstructured":"Tozzi AE, Asturias EJ, Balakrishnan MR, et al. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine. 2013; 31: 5041-6.","DOI":"10.1016\/j.vaccine.2013.08.087"},{"key":"1613","doi-asserted-by":"crossref","unstructured":"Psichogiou M, Samarkos M, Mikos N, Hatzakis A. Reactivation of varicella zoster virus after vaccination for SARS-CoV-2. Vaccines (Basel). 2021; 9: 6.","DOI":"10.3390\/vaccines9060572"},{"key":"1614","doi-asserted-by":"crossref","unstructured":"Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020; 79: 39-52.","DOI":"10.1136\/annrheumdis-2019-215882"},{"key":"1615","doi-asserted-by":"crossref","unstructured":"Bijlsma JW. EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs. Ann Rheum Dis. 2021. [Epub ahead of print].","DOI":"10.1136\/annrheumdis-2020-219773"},{"key":"1616","doi-asserted-by":"crossref","unstructured":"Lenfant T, Jin Y, Kirchner E, et al. Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients. Rheumatology (Oxford). 2021; 60: 5149-57.","DOI":"10.1093\/rheumatology\/keab139"},{"key":"1617","unstructured":"FDA. Shingrix 2021. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/shingrix"},{"key":"1618","doi-asserted-by":"crossref","unstructured":"Yanni EA, Ferreira G, Guennec M, et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012. BMJ Open. 2018; 8: e020528.","DOI":"10.1136\/bmjopen-2017-020528"},{"key":"1619","doi-asserted-by":"crossref","unstructured":"Curran D, Hunjan M, El Ghachi A, El-Hahi Y, Bianco V, Ferreira G. Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis. BMJ Open. 2019; 9: e023502.","DOI":"10.1136\/bmjopen-2018-023502"},{"key":"1620","doi-asserted-by":"crossref","unstructured":"Munoz-Quiles C, Lopez-Lacort M, Diez-Domingo J, Orrico-Sanchez A. Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009-2014. BMC Infect Dis. 2020; 20: 905.","DOI":"10.1186\/s12879-020-05648-6"},{"key":"1621","doi-asserted-by":"crossref","unstructured":"Matthews I, Duong M, Parsons VL, et al. Burden of disease from shingles and post-herpetic neuralgia in the over 80 year olds in the UK. PLoS One. 2020; 15: e0229224.","DOI":"10.1371\/journal.pone.0229224"},{"key":"1622","doi-asserted-by":"crossref","unstructured":"Chandler RE. Optimizing safety surveillance for COVID-19 vaccines. Nat Rev Immunol. 2020; 20: 451-2.","DOI":"10.1038\/s41577-020-0372-8"},{"key":"1623","doi-asserted-by":"crossref","unstructured":"Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2021. [Epub ahead of print].","DOI":"10.1136\/annrheumdis-2021-221490"}],"container-title":["Reumatismo"],"original-title":[],"link":[{"URL":"https:\/\/www.reumatismo.org\/index.php\/reuma\/article\/download\/1482\/936","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.reumatismo.org\/index.php\/reuma\/article\/download\/1482\/936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T11:45:20Z","timestamp":1651578320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.reumatismo.org\/index.php\/reuma\/article\/view\/1482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,5,3]]}},"URL":"https:\/\/doi.org\/10.4081\/reumatismo.2022.1482","relation":{},"ISSN":["2240-2683","0048-7449"],"issn-type":[{"value":"2240-2683","type":"electronic"},{"value":"0048-7449","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,3]]}}}